Collaboration partners and funding sources

Blakstad H, Brekke J, Rahman MA, Arnesen VS, Miletic H, Brandal P, Lie SA, Chekenya M, Goplen D (2023)
Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions
PLoS One, 18 (2), e0281166
DOI 10.1371/journal.pone.0281166, PubMed 36730349

Heggebø LC, Borgen IMH, Rylander H, Kiserud C, Nordenmark TH, Hellebust TP, Evensen ME, Gustavsson M, Ramberg C, Sprauten M, Magelssen H, Blakstad H, Moorthy J, Andersson K, Raunert I, Henry T, Moe C, Granlund C, Goplen D, Brekke J, Johannessen TA, Solheim TS, Marienhagen K, Humberset Ø, Bergström P et al. (2023)
Investigating survival, quality of life and cognition in PROton versus photon therapy for IDH-mutated diffuse grade 2 and 3 GLIOmas (PRO-GLIO): a randomised controlled trial in Norway and Sweden
BMJ Open, 13 (3), e070071
DOI 10.1136/bmjopen-2022-070071, PubMed 36940951

Leske H, Blakstad H, Lund-Iversen M, Skovholt EK, Niehusmann P, Ramm-Pettersen JT, Skogen K, Kongelf G, Sprauten M, Magelssen H, Brandal P (2023)
Astrocytoma (CNS WHO grade 4), IDH-mutant with co-occurrence of BRAF p.V600E mutation, and homozygous loss of CDKN2A
Neuropathology (in press)
DOI 10.1111/neup.12895, PubMed 36754566